Company profile
VERASTEM, INC.
NASDAQ:VSTMBiotechnology: Pharmaceutical Preparations
Drug pipeline (5)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) | approved | $10.0M*Q2 2024 | 0 | — |
| AVUTOMETINIB | phase3 | — | 9 | active |
| DEFACTINIB | phase3 | — | 13 | active |
| VS-4718 | phase1 | — | 2 | terminated, withdrawn |
| VS-5584 | phase1 | — | 2 | terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (27)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02372227 | phase1 | terminated | 2015-01-01 | 2015-10-01 | Verastem, Inc. | A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma |
| NCT07020221 | phase1_2 | recruiting | 2025-06-24 | 2028-12-01 | Verastem, Inc. | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors |
| NCT07659795 | phase2 | recruiting | 2026-07-28 | 2027-06-01 | Verastem, Inc. | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer |
| NCT07659782 | phase2 | recruiting | 2026-07-22 | 2027-06-01 | Verastem, Inc. | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer |
| NCT07644559 | phase2 | recruiting | 2026-06-16 | 2027-06-01 | Verastem, Inc. | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 219616 | 2025-05-08 | NDA | VERASTEM INC | |||||
Loading… | ||||||||